[Bio Story] Taeyeon Jeon, CEO of Alteogen: "Improving Patient Quality of Life Is the Essence"
Taeyeon Jeon, CEO of Alteogen, Interview ①
"ALT-B4, a Tool for Returning Patients to Normal Daily Life"
"Accumulated Validation Data Compresses Technology Transfer Timeline"
"The greatest value of Alteogen's technology lies in alleviating the emotional pain and daily inconveniences that patients endure during difficult treatments like cancer therapy."
Taeyeon Jeon, CEO of Alteogen, made this statement in an interview with The Asia Business Daily at the company's headquarters in Yuseong-gu, Daejeon, on the 23rd of last month. He believes that the core of Alteogen's subcutaneous injection (SC) formulation conversion technology, 'ALT-B4,' should be found not only in revenue generation and technological advancement, but primarily in 'improving patients' quality of life.' For cancer patients who otherwise have to spend all day in the hospital's infusion center for intravenous (IV) infusions or drag heavy IV bags to the bathroom, their arduous daily routine can be completely transformed through the conversion to SC formulations.
Taeyeon Jeon, CEO of Alteogen, is being interviewed at the Alteogen headquarters in Yuseong-gu, Daejeon, on the 23rd of last month. He emphasized that Alteogen's platform technology enables not only industrial value but also emotional healing for patients. Photo by Donghoon Jung
View original imageThe subcutaneous injection formulation utilizing Alteogen's technology allows the drug to be administered in just a few minutes into the fatty layer beneath the skin of the abdomen or thigh. This drastically increases convenience, as patients can immediately return to their normal daily activities right after administration.
Jeon emphasized, "Cancer patients experience tremendous stress as they live with a 'chemo port' inserted in their chest and tubes attached, making even showering difficult. Our technology fundamentally changes the method of administration, giving patients their ordinary daily lives back. Furthermore, it frees them from the psychological burden and emotional pain of being a 'patient' gathering at hospitals for injections."
A chemo port refers to a cylindrical coin-sized device (port) implanted under the skin below the clavicle, connected via a catheter system to a large blood vessel near the heart, to facilitate repeated administration of anticancer drugs, transfusions, and blood sampling.
This patient-centered technological capability and overwhelming productivity have led to strong partnership offers from global big pharma companies. In the first quarter of this year alone, Alteogen signed two licensing agreements with global pharmaceutical firms and is making steady progress.
Jeon stated, "It is not merely about market conversion rates; doctors and patients are directly experiencing the usefulness of our technology in clinical practice. In the past, we had to work hard to have our technology validated, but now, global partners are the first to acknowledge the commercial viability and stability of our solutions, marking a significant shift in our standing."
Jeon also expressed strong confidence in the industry's hot topic of converting antibody-drug conjugates (ADC) to SC formulations. He explained, "We have overcome the potential issues that can arise when converting highly toxic ADCs to subcutaneous injections through our unique proprietary methods, thereby maintaining efficacy while enhancing safety."
On the back of this technological edge, Alteogen's global licensing (license-out) activities are progressing faster than ever before. Jeon stressed that technology transfers with global pharmaceutical companies are by no means a simple process. Typically, a technology transfer starts with a Material Transfer Agreement (MTA), followed by a three-to-four-month testing period in which the partner company applies Alteogen's technology to its own drug candidates.
If the results are successful, the parties then discuss a 'Non-binding Term Sheet' outlining approximate upfront payments and milestone payments. This is followed by opening a 'data room'—a confidential information sharing space—where rigorous due diligence is conducted over several months on quality control (QC), regulatory approval, intellectual property, and other matters through a series of Q&A sessions.
This process alone can easily take two to three years, but recently the situation has changed dramatically. Jeon explained, "In the past, it took years to reach a definitive agreement, but after large-scale deals with companies like Merck (MSD), a standardized contract structure has been established and a wealth of validated data has accumulated, significantly shortening the negotiation period."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
More partners are now signing option contracts that allow them to conduct due diligence and testing in parallel, speeding up the process to avoid clinical delays. Jeon said, "This year, we anticipate the largest and most numerous licensing agreements in the company's history."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.